Evotec Names Dr Tim Tasker Executive Vice President Clinical Development and Member of the Executive Committee

Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced the appointment of Dr Tim Tasker as Executive Vice President Clinical Development and a member of its Executive Committee. He will lead Evotec's clinical development activities. Evotec has created this position following the acquisition of Evotec Neurosciences and the implementation of its strategy to increasingly focus on internal drug development with a focus on CNS diseases.
 
Dr Tasker, 52, will join Evotec with effect from 11 July 2005. He is a MD by training and brings more than 23 years of global clinical development and business expertise at Beecham, SmithKline Beecham (SB) and now GlaxoSmithKline (GSK), one of the leading pharmaceutical companies worldwide, to the Company. Most recently, Dr Tasker was Vice President Global Clinical Units, Clinical Pharmacology and Discovery Medicine and Member of the GSK Global Safety Board.
 
During his career Dr Tasker has gained deep drug development expertise at all stages. He has a strong background in clinical pharmacology and a particular ability in early development to proof-of-concept in man (Phase I, Phase IIa and Clinical Pharmacology Programmes). Through most of the 90s he headed SB's clinical pharmacology across Europe, where he was responsible for the design and implementation of early development plans for 50% of SB's portfolio. In addition, Dr Tasker was a key member of the Neurosciences Therapeutic Area Team. In this role he reviewed all in-licensed compounds and contributed to the selection of new molecules, their prioritisation and development planning together with the strategy for commercialisation of every neurosciences compound in SB's portfolio. In his career he has overseen more than 40 different compounds of many different pharmacologies moving from discovery into early development.
 
Dr Tasker has a Physiological Sciences first Class Honours Degree (BA Hons) from University of Oxford and a Medical Degree (MBBS) from London University, England. He is a Fellow of the Royal College of Physicians of the UK, and a Fellow and member of the Board of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians.
 
Joern Aldag, President and Chief Executive Officer of Evotec, said: "We are extremely delighted that Tim will join Evotec AG. He is an ideal candidate for this position as his qualification and experience ideally fit in the strategic focus of our company. Tim has a particular ability in bringing molecules into man and up to proof of concept, the phase of drug development Evotec is most actively involved. In addition, he has a deep insight and understanding of CNS related diseases, the area we are focussing on. With this background he will further strengthen our management team in an area which is one of the most important in our further development and help Evotec build a sustainable CNS focused pipeline."

Contact: Anne Hennecke, Director, Investor Relations & Corporate Communications, Evotec AG, Phone: +49-40-56081-286, anne.hennecke@evotec.com
Contact: Anne Hennecke, Director, Investor Relations & Corporate Communications, Evotec AG, Phone: +49-40-56081-286, anne.hennecke@evotec.com